NAACCR Item #3938: ALK Rearrangement

Item # Length Source of Standard Year Implemented Version Implemented Year Retired Version Retired
3938 1 NAACCR 2021 21

NAACCR XML: Tumor.alkRearrangement

Description
Testing for ALK rearrangement is performed for patients with advanced non-small cell lung cancer (NSCLC) to identify tumors which are sensitive to small-molecule ALK kinase inhibitors.
Rationale
ALK rearrangement is recommended by treatment guidelines for patients with advanced lung cancer as a prognostic marker and factor in determining appropriate therapy. It is a new data item for cases diagnosed 01/01/2021+.
Codes
0 Normal
ALK negative
Negative for rearrangement, no rearrangement identified, no mutations (somatic) identified, not present, not detected
1 Abnormal Rearrangement identified/detected: EML4-ALK, KIF5B-ALK, TFG-ALK, and/or KLC1-ALK
2 Rearrangement identified/detected: Other ALK Rearrangement not listed in code 1
4 Rearrangement, NOS
7 Test ordered, results not in chart
8 Not applicable: Information not collected for this case
If this information is required by your standard setter, use of code 8 may result in an edit error.
9 Not documented in medical record
ALK Rearrangement not assessed or unknown if assessed
Blank Diagnosis year is prior to 2021
Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.